Muscle wasting in chronic kidney diseases (CKDs), sometimes referred to as protein
energy wasting or cachexia, has been widely studied, yet much remains to be understood
about the underlying pathophysiology. CKD-related changes in cell signaling disrupt
proteostasis by activating muscle proteolysis [e.g. ubiquitin–proteasome system (UPS),
autophagy and caspase-3] and negatively impacting protein synthesis and muscle regeneration.
Muscle mass is controlled by a variety of signaling pathways, the most prominent being
the insulin-GF-1)/Phosphatidylinositide 3-kinase (PI3K)/Protein Kinase B (Akt) pathway,
which provides a point of intersection for protein synthesis, protein degradation
and myogenesis. Akt phosphorylates and activates mTOR, which in turn stimulates key
components of the protein synthesis and myoblast differentiation machineries. In contrast,
Akt phosphorylates and inhibits the Forkhead box class O (FOXO) transcription factors,
which increase the expression of several atrophy-inducing proteins including atrogin-1/MAFbx
and Muscle RING finger 1 (MURF1) [1]. Other important signaling pathways include the
Janus kinase/signal transducers and activators of transcription (JAK/STAT) and Activin
receptor-IIB (ActRIIB)/SMAD pathways, which mediate the effects of cytokines [e.g.
interleukin-6 (IL-6)] and the muscle-specific autocrine factor, myostatin (also called
GDF-8), respectively [2].
In the past decade, we have begun to understand how changes in cell signaling and
metabolic pathways are coordinately regulated by microRNAs (miRNAs), small RNAs that
bind to complimentary sequences in messenger RNA (mRNA) 3′-untranslated regions. This
interaction can either facilitate mRNA degradation or silence translation of the mRNA
into protein [3, 4]. Emerging evidence indicates that miRNAs play important roles
in the development and repair of muscle as well as the normal maintenance of mature
muscle fibers. Because of their small ‘functional’ or seed unit of six to eight nucleotides,
miRNAs typically target multiple proteins, and frequently, the targets are in the
same signaling pathway. This is particularly true for the IGF-1/PI3K/Akt and myostatin/SMAD
pathways, both of which modulate key steps in protein synthesis and degradation. Expression
of YY1 and other regulators of muscle satellite cell function and differentiation
are also modulated by miRNAs [5]. In this issue of Nephrology Dialysis Transplantation,
Robinson et al. [6] review how miRNAs contribute to normal muscle development, the
control of muscle protein turnover in CKD and CKD-associated interorgan cross talk.
They also discuss how miRNAs represent future potential therapeutic agents for treating
muscle pathologies [6].
Alterations in miRNAs have been linked to dysfunctional proteostasis in skeletal muscle
during CKD [7–10]. MiR1, miR-133 and miR-206 are increased in CKD and negatively regulate
the early steps of the IGF-1/PI3K/Akt pathway. In contrast, miR-23a, miR-27a and miR-486
are decreased and modulate cell signaling mediators and atrogenes (i.e. atrogin-1/MAFbx).
Interestingly, miR-23a and miR-27a, along with miR-24a, are located in a single cluster
on the chromosome (chromosome 19 in humans and chromosome 8 in mice) [9, 11]. They
are transcriptionally controlled by a single promoter and transcribed as a single
RNA that is processed into individual miRNAs. miR-23a and miR-27a target muscle-specific
atrophy-inducing enzymes associated with the UPS. They also target suppressors of
the IGF-1/PI3K/Akt pathway including myostatin, a proteostasis-disrupting myokine
member of the Transforming Growth Factor-β (TGF-β) superfamily that activates the
SMAD pathway. In addition to direct actions on muscle, myostatin impairs muscle precursor
cell proliferation and the regenerative capacity of muscle, which is decreased in
CKD. miR-133 similarly impacts myoblast proliferation differentiation through actions
on IGF-1 and IGF-1R [3].
Although the focus of the article by Robinson et al. [6] is largely on the miRNAs
that disrupt proteostasis, it is important to be reminded how other signals such as
mitochondrial dysfunction and inflammation play prominent roles in CKD-related cachexia.
Inefficiencies in mitochondrial function lead to skeletal muscle weakness and decreased
exercise capacity in CKD patients [12] and animals [13]. In CKD, reduced mitochondrial
number and mass, as well as mitochondrial damage and dysfunction, are linked to atrophy-inducing
responses, including increased oxidative stress and autophagy/mitophagy. Reduced Peroxisome
proliferator-activated receptor gamma coactivator 1-α (PGC-1α) and an increase in
BNIP3 lead to reduced mitochondrial biogenesis and ATP production [13]. PGC-1α is
a key transcriptional coactivator that is important for mitochondrial biogenesis [14]
and BNIP3 is a pro-apoptotic protein localized in the outer mitochondrial membrane.
It regulates the opening of the mitochondrial permeability pore and is linked to intrinsic
apoptosis [15]. Consistent with an increase in BNIP3, Du et al. [16] found that elevated
caspase-3 activity in muscle of CKD rats contributed to their excessive proteolysis.
In other studies, Su et al. [13] reported that the level of BNIP3 was linked to the
deterioration of mitochondrial function and decreased ATP production. Using in vivo
magnetic resonance and optical spectroscopy, Roshanravan et al. [17] found that resting
oxygen consumption was elevated and mitochondrial coupling was lower in early CKD
patients. Tamaki et al. [18, 19] also reported a decline in muscle mitochondria and
exercise endurance occurs early in CKD mice. These findings, when coupled with the
CKD-induced decrease in PGC-1α, are compelling evidence that mitochondrial dysfunction
contributes to CKD cachexia.
Inflammation is another prominent mediator for the wasting process in CKD. Production
of inflammatory cytokines [i.e. tumor necrosis factor (TNF)-α and IL-6] by myofibers
and other cell types (e.g. macrophages) is increased in CKD and they act in a paracrine/endocrine
fashion on both myofibers and satellite cells [20]. Inflammatory cytokines (e.g. TNF-α)
activate nuclear factor-κB, which in turn induces transcription of key atrogenes in
myofibers and inhibits the MyoD differentiation factor in myoblasts [20, 21]. TNF-α
also increases myostatin expression and induces apoptotic signaling, both of which
exacerbate the muscle catabolism processes already described. IL-6 also is a causative
agent of CKD cachexia, although its role in the muscle may be somewhat variable and
situational. There are substantial data indicating that IL-6 induces muscle wasting
[22]. Others have reported that increased IL-6 facilitates local infiltration of macrophages,
which upregulate locally produced IGF-1 and limited muscle loss in CKD mice [23].
In humans, an increase in IL-6 was associated with increased muscle protein synthesis
during hemodialysis [24].
Exercise is one of a few interventions shown to help maintain muscle mass while also
slowing or improving kidney function in CKD [25, 26]. Recent studies of the mechanisms
underlying the effects of exercise in CKD have revealed an interesting and powerful
communications network between muscle and other organs, including kidney (i.e. cross
talk). Cross talk between organs provides advantages or disadvantages, depending on
the mediators involved. This interorgan communication typically occurs via production
and release of proteins, lipids, metabolites and/or nucleic acids. In one example
of protein exchange, Peng et al. [27] uncovered a link between the CKD-related reduction
of the exercise-responsive PGC-1α transcription coactivator in muscle and irisin,
a myokine that impacts oxidative metabolism in muscle and other organs [27]. Using
a folate model of acute kidney injury, they found less kidney damage in mice that
overexpress PGC-1α in muscle only versus normal controls. The group then used recombinant
irisin to confirm that the myokine was responsible for the improvement in mitochondrial
respiration, energy metabolism and reduced fibrosis in damaged tubule cells.
As discussed by Robinson et al. [6], there is compelling evidence for a role of miRNAs
in the beneficial effects of exercise. In a recent study, acupuncture with low-frequency
electrical stimulation (Acu/LFES) ameliorated hind limb muscle loss due to CKD in
mice [23]. The mechanism involved the upregulation of the IGF-1/PI3K/Akt pathway in
both myofibers and muscle satellite cells [23]. In a follow-up study, miR-181 was
increased in hind limb muscles and serum exosomes following Acu/LFES [28]. Surprisingly,
the Acu/LFES procedure also increased renal blood flow in CKD mice and the response
was limited by blocking exosome secretion. The group then demonstrated that miR-181
targets angiotensinogen and that renal angiotensinogen protein was lower in cachexic
mice following Acu/LFES. In an unrelated study, resistance exercise in the form of
synergistic ablation attenuated CKD-induced muscle loss and increased the levels of
miR-23a and -27a in muscles. Using a streptozotocin model of diabetic muscle atrophy
and reduced renal function, the investigators found that overexpression of miR-23
and miR-27 in muscle improved renal function as evidenced by a reduction in blood
urea nitrogen (BUN) and reduced levels of renal fibrosis [29]. As in the Acu/LFES
studies, the mechanism for the improvement in renal function and fibrosis involved
exosome-mediated delivery of miR-23a and miR-27a to the kidney. Together with the
irisin study by Peng et al. [27], these findings provide some of the strongest evidence
to date for muscle–kidney cross talk.
There are challenges with using miRNAs as therapeutic agents. Free RNAs are rapidly
degraded and miRNAs need to be targetable to minimize undesirable side effects. Encapsulation
of miRNAs into extracellular vesicles makes them more stable and provides a means
to target them. Wang et al. developed a novel approach to this challenge [7, 10].
They maintained muscle satellite cells in culture and used molecular biological tools
to provide the cells with a desired miRNA and to produce exosomes with cell-targeting
peptides embedded in their membranes [7, 10]. These ‘engineered’ exosomes were collected
from the media of the satellite cells and then injected into a single hind limb muscle
of mice with unilateral ureteral obstruction-induced kidney injury and muscle atrophy.
The therapy reduced both muscle loss and renal fibrosis. Fluorescent tags from the
collected and labeled exosomes were found in both uninjected muscles and kidneys of
treated mice. This approach has the potential to serve as a foundation for individualized
treatments in patients using their own satellite cells.
In conclusion, Robinson et al. [6] provide a thoughtful overview of the emerging role
of miRNAs in skeletal muscle wasting of CKD. In some cases, inconsistencies in study
outcomes diminish our ability to draw strong conclusions. For example, levels of total
and specific miRNAs in CKD patient serum have been reported to either increase or
decrease [30, 31]. Outcome variability may result from the use of different analytic
methodologies or different underlying etiologies. These discrepancies underscore the
need for more comprehensive studies in cell models, animals and especially in patients
to validate and confirm how specific miRNAs change with CKD. Such studies will better
enable us to fully evaluate the therapeutic potential of miRNAs as a modality to limit
the progression of CKD and the associated cachexia.
CONFLICT OF INTEREST STATEMENT
None declared. The authors have nothing to disclose. The text of this editorial has
not been published previously.
(See related article by Robinson et al. Skeletal muscle wasting in chronic kidney
disease: the emerging role of microRNAs. Nephrol Dial Transplant 2020; 35: 1469--1478)